Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sawai Group Holdings CoSWGHF 53 Debt-to-EBITDA is 6.19 as of Mar. 2026, which is 175% above its 10-year median of 2.25. GuruFocus rates SWGHF with a GF Score™ of 53/100 and a GF Value™ of $15.98. The stock has 3 warning signs investors should review. Among 691 Drug Manufacturers companies, Sawai Group Holdings Co ranks worse than 70.62% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sawai Group Holdings Co's Debt-to-EBITDA or its related term are showing as below:
SWGHF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.57 Med: 2.25 Max: 4.7
Current: 3.28
During the past 5 years, the highest Debt-to-EBITDA Ratio of Sawai Group Holdings Co was 4.70. The lowest was -3.57. And the median was 2.25.
SWGHF's Debt-to-EBITDA is ranked worse than 70.62% of 691
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs SWGHF: 3.28
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sawai Group Holdings Co Debt-to-EBITDA Related Terms
Sawai Group Holdings Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sawai Group Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sawai Group Holdings Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sawai Group Holdings Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sawai Group Holdings Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Sawai Group Holdings Co (SWGHF) has a Debt-to-EBITDA of 6.19 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sawai Group Holdings Co. This is 175% above median its historical median of 2.25. According to the industry distribution chart, Sawai Group Holdings Co ranks #488 out of 691 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is Sawai Group Holdings Co's Debt-to-EBITDA too high?
Sawai Group Holdings Co's current Debt-to-EBITDA of 6.19 is 175% above median its 10-year median of 2.25. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Sawai Group Holdings Co's value of 6.19 is 268.5% above this industry median. Based on the distribution chart, Sawai Group Holdings Co ranks #488 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sawai Group Holdings Co has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Sawai Group Holdings Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sawai Group Holdings Co ranks #488 out of 691 companies for Debt-to-EBITDA. This places Sawai Group Holdings Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Sawai Group Holdings Co's value of 6.19 is 268.5% above this benchmark. While the company's 10-year median is 2.25 vs. the industry median of 1.68, Sawai Group Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sawai Group Holdings Co's current Debt-to-EBITDA of 6.19 is 268.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sawai Group Holdings Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sawai Group Holdings Co's current Debt-to-EBITDA is 6.19, which is 175% above median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sawai Group Holdings Co stock overvalued right now?
Sawai Group Holdings Co (SWGHF) has a current Debt-to-EBITDA of 6.19. The stock's GF Value™ is $15.98, compared to a current price of $11.52 — trading 27.9% below its estimated fair value. The current Debt-to-EBITDA is 6.19, which is 175% above median its 10-year median of 2.25 and 268.5% above the Drug Manufacturers industry median of 1.68. Sawai Group Holdings Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sawai Group Holdings Co (SWGHF), the current Debt-to-EBITDA is 6.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sawai Group Holdings Co (SWGHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sawai Group Holdings Co stock appears to be undervalued.
The current stock price of $11.52 is trading 27.9% below its estimated GF Value™ of $15.98.
Key valuation signals for SWGHF:
Debt-to-EBITDA: 6.19 (175% above median its 10-year median of 2.25)
GF Value™: $15.98 vs. price of $11.52 (27.9% below fair value)
Industry Position: 268.5% above the Drug Manufacturers median (#488 of 691)
No single metric tells the full story. See the SWGHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sawai Group Holdings Co Ltd is engaged in providing management support or guidance to domestic and foreign companies engaged in businesses related to medical and healthcare services, such as the manufacture and sale of pharmaceutical products and medical equipment, as well as various businesses incidental or related to the same.
53GF Score
Get the complete analysis for SWGHF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWGHF has been successfully added to your 
